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Abstract
Purpose of Review This review summarises and discusses the
epidemiological evidence suggesting a causal relationship be-
tween sleep duration and cardio-metabolic risk and outcomes
in population.
Recent Findings Sleep duration is affected by a variety of
cultural, social, psychological, behavioural, pathophysiologi-
cal and environmental influences. Changes in modern socie-
ty—like longer working hours, more shift-work, 24/7 avail-
ability of commodities and 24-h global connectivity—have
been associated with a gradual reduction in sleep duration
and sleeping patterns across westernised populations. We re-
view the evidence of an association between sleep distur-
bances and the development of cardio-metabolic risk and dis-
ease and discuss the implications for causality of these
associations.
Summary Prolonged curtailment of sleep duration is a risk
factor for the development of obesity, diabetes, hypertension,
heart disease and stroke and may contribute, in the long-term,
to premature death.
Keywords Sleep deprivation . Cardiovascular disease .
Obesity . Diabetes . Hypertension . Naps
Introduction
Most creatures in the animal kingdom spend a significant
amount of time asleep. Humans tend to sleep for a third of
their lives. The amount required varies across the life course
with more time spent in infancy and childhood, eventually
settling into a pattern of 7 to 8 h per night. Sufficient sleep is
necessary for optimal daytime functioning, performance and
wellbeing, yet the amount of sleep that people get varies
greatly.
The duration of sleep shows secular trends alongside
changes in modern society that require longer hours of work,
more shift work and “24/7” availability and use of commod-
ities. These changes have reduced the average duration of
sleep and modified the patterns of sleep across westernised
populations, with increased reporting of fatigue, tiredness
and excessive daytime sleepiness. Data published from the
National Sleep Foundation suggest a significant decline in
the average duration of sleep of Americans in the last
100 years, with a loss of about 1.5 h per night, from the
average 9.0 h per night in 1910 to the average 7.5 h per night
reported in 2014. This sleep curtailment has been attributed by
many mainly to lifestyle changes.
Sleep and Self-Reported Ill Health
Epidemiologic studies of self-reported sleep and health status
began to appear about 50 years ago. However, in the last
20 years, there has been an explosion of population science
on the relationship between sleep duration and a variety of
health outcomes, and the implications for public health have
become apparent [1••]. An exploratory study using an anony-
mous questionnaire probing self-reported sleep and ill-health
in over 17,000 college students, aged 17–30 years, from 27
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non-health-related universities from 24 countries, showed that
short sleep durations (less than 7 h per night) were associated
with poorer self-rated health in men and women, while longer
sleep durations were not [2]. Countries with the shortest sleep
duration had the worst self-rated health (all in the Far East
Asia) with 30–40% ill health in Japan and South Korea and
20–30% in Thailand and Taiwan. These results clearly do not
imply a causal relationship but point to a new interest in the
health and social implications of sleep deprivation and the
potential importance for public health.
Short Sleep and Obesity
In the last few decades, there has been a significant increase in
the prevalence of obesity worldwide and the World Health
Organization has declared it a global epidemic. The rise in
obesity has been paralleled by a steady constant reduction in
the average sleep time, as indicated by the results of national
surveys in USA in the last century [3]. The ‘inverse’ parallel
trends have sparked a new interest in exploring the possible
connection between these two distinct and apparently inde-
pendent patterns.
Children and Adolescents
Obesity in childhood has reached epidemic proportions in
recent years and is a cause of physical and psychological
problems, including low self-esteem. It often continues into
adulthood, where it causes major morbidity, disability and
premature death, including type 2 diabetes and cardiovascular
disease. Several studies have reported associations between
short sleep duration and the risk of obesity in children and
adolescents, with increased estimated risk as high as 90%
[4•]. The early studies have been predominantly cross-section-
al, i.e. theymeasured duration of sleep and presence of obesity
at the same time point, and therefore, whilst suggestive of
possible relationships, were unable to support a cause-effect
association. In other words, their results could have been con-
sistent with two hypotheses: that a reduced duration of sleep
could be the cause of obesity or, on the contrary, that obesity
was the main cause of reduced sleep [5]. Both explanations are
plausible. It is important, therefore, to ascertain whether the
reduced duration of sleep (the exposure of interest) preceded
the development of obesity (the outcome of interest). To ad-
dress the temporal sequence whereby the ‘exposure’ of inter-
est should precede the ‘outcome’ to support a link of ‘causal-
ity’, as indicated by Sir Austin Bradford Hill [6], prospective
longitudinal studies in children have shown that short duration
of sleep may indeed precede the development of overweight
or obesity, in support of a plausible causal link between short
duration of sleep and the development of obesity [7]. The
potential public health implications of a causal association
would be far reaching. However, whilst highly encouraging,
these studies had limitations in that sleep assessment had often
been based on parental reports or self-reports rather than on
direct measurements, and body mass index had been the main
outcome measure of obesity. More recently, however, more
objective measures of sleep—using actigraphy—and more
specific measures of adiposity (fat mass vs lean body mass)
seem to confirm the association originally described [8].
Adults
Short sleep is also associated with the risk of obesity in cross-
sectional studies of adults (approx. 55%) [4•]. However, pro-
spective studies are less clear in establishing the temporal
sequence and further studies are still on-going [9]. One reason
offered to explain why the prospective association is less clear
is that with time, additional more powerful factors (physical
inactivity, overfeeding) intervene, masking the effect of sleep
deprivation in the determination of weight gain.
HowWould Short Duration of Sleep Cause Obesity?
There are several lines of evidence to suggest plausible mech-
anisms. In short-term, experiments in healthy volunteers, se-
vere sleep deprivation causes an increase in energy intake and
a reduction in energy expenditure through activation of hor-
monal responses that regulate appetite and energy balance [10,
11•]. During sleep deprivation, there are reciprocal changes in
leptin, a hormone produced by fat cells (adipocytes) that reg-
ulate energy stores and satiety, and ghrelin, a hormone pro-
duced by the stomach that enhances appetite. These two hor-
mones regulate hunger and satiety. In normal circumstances,
when energy stores are low and the stomach is empty, leptin
falls and ghrelin increases to stimulate energy intake and ap-
petite. Conversely, when the body has accumulated enough
energy through food, leptin increases and ghrelin falls. During
sleep deprivation, this system is activated so that leptin is
suppressed and ghrelin is stimulated, determining hunger, in-
creased appetite and greater energy intake and storage in adi-
pocytes with concomitant reduction in energy [10, 12]. These
responses to sleep deprivation, if sustained over a longer pe-
riod of time, would facilitate weight gain. Sleeping less would
also give people more time to eat and to engage in other
sedentary activities, as exemplified by children and adoles-
cents who like to stay up late to play on their computer or
watch TVor to interact with social networks whilst snacking
[13, 14].
In principle, the associations seen between sleep depriva-
tion and overweight or obesity is open to the possibility of a
‘reverse causality’ pathway [5], whereby obesity causes short
or disrupted sleep (or both) because of breathing problems at
night and the effect of inflammatory markers on the brain’s
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regulation of the circadian rhythm [15]. The results of con-
trolled intervention studies in healthy volunteers, the results of
prospective associations between short sleep duration and
weight gain and the compelling evidence on other metabolic
effects lend support to the first ‘causal hypothesis’.
Short Sleep, Glucose Metabolism and Diabetes
Type 2 diabetes (the commonest form of diabetes in the world)
is a chronic condition characterised by the inability of the
body to utilise glucose from the circulation (glucose intoler-
ance) with the result of high circulating levels of glucose in the
bloodstream (hyperglycaemia). This is caused by either a re-
sistance of the peripheral tissues (especially muscle) to the
action of the hormone insulin to take up glucose into the cell
(insulin resistance) or to the lack of appropriate production of
insulin from the pancreas in response to a glucose load. One of
the most important risk factors for the development of type 2
diabetes is overweight or obesity. The latter is characterised by
an increasing degree of glucose intolerance due to insulin
resistance, eventually leading to overt type 2 diabetes.
Diabetes is one of the most powerful, though preventable,
causes of cardiovascular diseases (i.e. coronary heart disease,
stroke and kidney disease).
Short Sleep and Glucose Metabolism
Short-term, acute, laboratory and cross-sectional observation-
al studies indicate that disturbed or reduced sleep is associated
with glucose intolerance, insulin resistance, reduced acute in-
sulin response to glucose and a reduction in the disposition
index, thus predisposing individuals to type 2 diabetes [11•].
Moreover, the samemetabolic dysregulations can be observed
in association with disruptions in sleep quality [11•]. These
acute observations are fully reversible when sleep duration is
restored. Therefore, the effects of acute, short-term sleep dep-
rivation or disruption are reversible. Yet, many individuals
believe they adapt to chronic sleep loss as easily or that recov-
ery requires only a single extended sleep episode. This is not
the case. The cumulative detrimental effects of sustained and
prolonged chronic sleep loss (deprivation) are not reversed, so
that prolonged life-style habits of sleep curtailment may lead
to long-term adverse health and safety consequences [16].
Finally, prolonged sleep restriction with concurrent circadian
disruption decreases resting metabolic rate and increases post-
prandial plasma glucose (from inadequate insulin secretion)
[17]. So, sleeping less and at the wrong time of the circadian
cycle has compounding negative effects on glucose and insu-
lin metabolism.
This area of research has produced convincing evidence of
the direct influence of sleep on metabolic, as well as genetic,
pathways. In the first clinical study linking sleep restriction to
an alteration of a molecular metabolic pathway, the authors
studied seven healthy volunteers in a randomised crossover
trail of 4 days of sleep deprivation (4.5 h per night) and 4 days
of normal sleep (8.5 h per night). Theymonitored the stages of
sleep with polysomnography and adherence to bed-time with
actigraphy. Caloric intake and meals were kept constant
throughout the study. At the end of each period, the partici-
pants underwent an intravenous glucose tolerance test
(IVGTT)—to measure total body insulin sensitivity—and a
subcutaneous abdominal fat biopsy to isolate adipocytes.
The researchers then exposed the adipocytes ‘in vitro’ to in-
cremental insulin concentrations to measure the ability of in-
sulin to increase the phosphorylation of Akt, an important step
in the insulin-signalling pathway [18••]. The results show that
sleep deprivation is associated with a 30% reduction in the
phosphorylation of Akt, indicating reduced peripheral insulin
response. This was paralleled by an expected reduction in total
body insulin sensitivity. These results substantially challenge
the traditional views that the primary purpose of sleep is con-
fined to restorative effects on the central nervous system,
pointing to a much wider influence of sleep on bodily func-
tions, including metabolism, adipose tissue, cardiovascular
function and possibly more [19].
To further this concept, there is evidence, using gene tran-
scriptome analysis, that sleep restriction can up- and down-
regulate the expression of genes mainly associated with not
only circadian rhythms and sleep homeostasis (rather expect-
ed), but also with those involved in oxidative stress and me-
tabolism [20•].
Short Sleep and Diabetes
From the experimental data discussed, we can summarise as
follows: in short-term, acute, laboratory and cross-sectional
studies, disturbed or reduced sleep is associated with glucose
intolerance, insulin resistance, reduced acute insulin response
to glucose and a reduction in the disposition index, reduced
peripheral insulin response and up- and down-regulation of
the expression of genes involved in metabolic pathways, all
predisposing factors to the development of type 2 diabetes.
It is, therefore, obvious to ask the question: does sleep
deprivation predict the risk of developing type 2 diabetes?
The causality of the association, the generalizability of the
results and their extrapolation to longer-term effects of
sustained sleep disturbances, however, will require the verifi-
cation that short sleepers have a greater risk of developing
type 2 diabetes in prospective population studies to establish
a temporal sequence between exposure and outcome (exclud-
ing reverse causality).
The aggregate analysis of prospective longitudinal studies
carried out in populations around the world supports the con-
cept that individuals who sleep less than 6 h per night have a
28% greater risk of developing type 2 diabetes compared to
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those sleeping 6–8 h per night [21•]. The risk is even greater
when disrupted quality of sleep is considered (as difficulty in
initiating or maintaining sleep), with risks estimated to rise to
57 and 84%, respectively. A recent systematic review and
meta-analysis of 36 studies involving over 1 million partici-
pants compared the risk associated with sleep disturbances
and diabetes with that associated with other traditional risk
factors, like overweight, family history and physical inactivity
[22]. The analysis showed that the risk of developing type 2
diabetes in people with sustained sleep deprivation was com-
parable to that attributable to other well-known cardio-meta-
bolic risk factors.
Short Sleep and Hypertension
What Is Hypertension?
High blood pressure (or hypertension) is a leading global
health risk [23]. It is the largest known risk factor for cardio-
vascular disease (coronary heart disease, stroke, kidney dis-
ease and vascular dementia) and related disability. Often de-
scribed as ‘silent killer’ because it rarely causes symptoms,
high blood pressure had a global age-standardised prevalence
of 24% (1 in 4) in men and 20% (1 in 5) in women in 2015
[23]. The number of adults with hypertension increased from
594 million in 1975 to 1.13 billion in 2015, with the increase
largely seen in low- and middle-income countries [23].
In high-income countries, like the USA and the UK, about
half of the adult population do not know what their blood
pressure is. Of those with hypertension, more than 50% are
unaware of it, and of those who take treatment, only a third
shows good blood pressure control. In low- and middle-
income countries, the picture is much worse [24].
Up to 80% of premature death from cardiovascular disease
can be prevented through better public health. Whilst some
risk factors (age, ethnicity, gender, genetics) cannot be modi-
fied, addressing modifiable risk factors will yield significant
health and economic gains. Reducing excessive dietary salt,
improving poor diet and reducing obesity, avoiding excessive
alcohol consumption, increasing level of physical activity and
improving socio-economic conditions and mental health are
all cost-effective public health interventions.
When these actions are not sufficient, drug therapy is used
to reduce blood pressure and the burden of cardiovascular
complications.
Role of Sleep
In physiological conditions, our blood pressure follows a di-
urnal pattern with a fall at night whilst we rest and sleep
(referred as ‘nocturnal dip’). This fall is due to a variety of
mechanisms, including supine position, muscle relaxation and
reduced sympathetic tone. However, in recent years, it has
become apparent that many individuals may not present the
expected nocturnal dip in blood pressure (‘non-dippers’). This
phenomenon may present both in those with normal ‘day-
time’ blood pressure as well as in those with high ‘day-time’
blood pressure. Non-dippers have a higher risk of developing
cardiovascular disease compared to dippers [25].
Early findings from British and American studies suggest
associations between sleep duration and hypertension risk.
Specifically, cross-sectional analyses showed a significant,
consistent association between short sleep duration (< 5 h
per night) and risk of hypertension. In some studies, the asso-
ciation was stronger among women [26], which was attenuat-
ed in prospective analyses after multivariate adjustment [27].
A recent review of the available studies estimates the risk of
developing hypertension in short sleepers at 21% [28] (Fig. 1).
The effect of sleep deprivation on the incidence of hyperten-
sion is detected also independently of the severity of sleep-
breathing problems (as measured by the apnoea-hypopnoea
index or AHI) [29]. The effect is detectable early in childhood
and adolescence affecting both day-time and night-time blood
pressure [30], suggesting that sleep disturbances not only raise
night blood pressure by disrupting sleep but exert prolonged
carryover effects on day-time blood pressure leading to hyper-
tension. Finally, in a group of elderly men studied with
polysomnography and followed-up for many years, it has
been established that short sleep is an independent predictor
of the development of hypertension predominantly because of
a significant reduction in slow-wave sleep, the restorative
stage of sleep [31].
An important step in epidemiological research to imply
causality is the evidence of ‘reversibility’, i.e. the evidence
that if one is able to modify the risk factor, the outcome
should be modified in the direction of the observed rela-
tionship. One of the main limitations in this field of re-
search is the absence of a standard validated tool for ex-
tending sleep (without the use of hypnotics or other phar-
macological agents) in a sustained manner. Sleep extension
can be achieved in a variety of ways, but it invariably will
involve multiple behavioural modifications aided by some-
what structural changes in the environment that surrounds
us and that exert pressure on our time and the opportunities
we have to engage in ‘sleep’. One encouraging experiment
was carried out with success in 22 participants with stage 1
hypertension who were randomised to either a 6-week pe-
riod aimed to increase bedtime by 1 h daily (sleep exten-
sion group) or to a 6-week period (sleep maintenance
group) aiming to maintain habitual bedtime [32]. During
the trial, the sleep extension group increased the sleep du-
ration (directly measured by actigraphy) by an average of
35 min per night compared to the sleep maintenance group.
At the same time, their blood pressure measured through-
out the 24 h was reduced by an additional 7/4 mmHg by
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the end of the interventions, suggesting a direct beneficial
effect of sleep extension on blood pressure.
Short Sleep and Other Conditions
Lipids
Blood lipid profiles characterised by high total cholesterol and
LDL-cholesterol, high triglycerides and/or low HDL-
cholesterol are well-established risk factors for cardiovascular
disease. They are also more commonly associated with other
metabolic abnormalities like obesity, insulin resistance and
diabetes. Some longitudinal evidence suggests an association
between short duration of sleep and an unfavourable pattern of
blood lipid profile, particularly detectable in adolescents [33].
However, a recent review of all the available evidence pooled
together, whilst suggesting a trend for a 10% greater risk of
developing hypercholesterolaemia in those sleeping 5 h or
less, does not provide unequivocal evidence for an indepen-
dent effect of sleep deprivation on lipid metabolism [34].
Vascular Calcifications
The concept of a possible causal link between sleep depriva-
tion and cardio-metabolic risk is strengthened by the evidence
obtained from the Coronary Artery Risk Development in
Young Adults (CARDIA) cohort in Chicago. In this study,
18- to 30-year-old black and white men and women were
studied and followed-up for 5 years. At baseline, sleep metrics
(wrist actigraphy measured duration and fragmentation, day-
time sleepiness, overall quality, self-reported duration) were
examined and a CT scan of their heart was carried out to
measure calcifications of their coronary arteries. A similar
CT scan was repeated 5 years later. After excluding the con-
founding effect of a variety of behavioural, life-style and
metabolic factors, participants who slept 5 h or less had a
sharp increase in the risk of developing coronary calcifica-
tions, risk factors for myocardial infarction (i.e. heart attacks).
The rate of development of calcification was 33% greater for
every hour of sleep curtailment [35]. The effect was twice as
strong in women as in men, although the reason for this gender
difference is not known.
Short Sleep and Health Outcomes
From what we have seen so far, it is apparent that sleep dep-
rivation—whether short- or long-term—is strongly and con-
sistently associated with a variety of biological mechanisms
(hormonal changes in regulation of energy balance and appe-
tite, activation of inflammatory markers, glucose intolerance
and insulin resistance, molecular effects in adipocytes, up- and
down-regulation of gene expression, vascular calcifications)
and risk factors (overweight and obesity, type-2 diabetes, hy-
pertension) that collectively are strong predictors of the like-
lihood to develop cardiovascular disease. If these associations
were to reflect cause-effect relationships, we would expect to
find that those who have long-term sleep deprivation (i.e.
those who regularly sleep less than the average for the popu-
lation) would be more likely to develop cardiovascular disease
(like coronary heart disease and stroke) and die more often
from it [36].
Coronary Heart Disease
In large population studies, people have been asked about
their sleeping habits and have been followed up for many
years, often decades, and their health outcomes have been
recorded carefully over the years. When these studies
have been put together and analysed, it has become ap-
parent that, despite the variability between studies due to
Fig. 1 Forest plots of the prospective associations between short duration
of sleep and the incidence of hypertension in population studies in
adults*. *Results are reported as risk ratio and 95% confidence
intervals. (Adapted by permission from Macmillan Publishers Ltd.:
Meng L et al. Hypertens Res 2013; 36: 985–95) [28]
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different populations, various methods of assessments
etc., those who were reporting shorter duration of sleep
(usually less than 5 or 6 h per night) were more likely to
experience episode of coronary heart disease and to die
from it when compared to those usually sleeping on aver-
age 6 to 8 h per night. The early studies indicate an av-
erage increase in risk of 48% [37••]. The risk of develop-
ing coronary heart disease is further enhanced if the short
sleep is also associated to poor quality sleep [38], sug-
gesting an independent role of quantity as well as quality
of sleep on cardiovascular risk.
Stroke
Similar to what was seen for coronary heart disease, short
sleepers display a greater risk of developing fatal and non-
fatal strokes over a long term [37], equivalent to an approxi-
mate 15% higher risk [39].
Mortality One of the most surprising result of the epidemiolog-
ical studies exploring the relationships between short duration of
sleep and health outcomes is the description of a 12% increased
risk of all-cause mortality in short sleepers [40••]. This finding
has been consistently confirmed in independent analyses from
different researchers and in different countries. These results, if
attributable to a direct cause-effect, would reinforce the general
concept that sleep is such a fundamental function in human bi-
ology that a sustained habit of insufficient sleep (currently esti-
mated as less than 5 to 6 h per day on a regular basis) would be a
likely contributor of premature death. It is of interest to highlight
that a careful study in a representative British population has
established that the higher risk of mortality that is seen in people
who tend to curtail their average sleeping time is duemainly to an
increase in cardiovascular mortality rather than non-
cardiovascular mortality [41•].
In summary, Fig. 2 puts together the current state of knowl-
edge that links sleep deprivation and health outcomes [42]. It
is immediately apparent that the traditional belief that sleep
pertains exclusively to the brain is being challenged by recent
evidence to suggest a much wider control that sleep exerts on
several organs and systems, from the heart to the kidney, the
metabolic pathways to adipose tissue to the vasculature. The
concept that sleep is an idle state of a suspendedmind closer to
a state of death must be abandoned. Sleep is an active physi-
ological process greatly needed by our body to sustain vital
functions, in the short as well as in the longer term. Its trading
for extra wakefulness is not without consequences.
Napping and Risk
A long-established practice in Mediterranean areas, day-
time napping—commonly known as ‘siesta’—is often
associated with good health through a postulated stress
relief mechanism. However, daytime sleepiness, often
characterised by daytime napping, has been regarded as
an early sign or risk indicator of a range of health prob-
lems, like depression, cognitive impairment, Parkinson
disease and other chronic debilitating illnesses. Whilst
early evidence in Mediterranean countries suggested that
‘siesta’ would be associated with favourable cardiovascu-
lar outcomes [43], the contemporary association between
daytime napping and mortality risk is uncertain. Most
previous studies have come from Mediterranean coun-
tries, in which the incidence of and the rate of death from
cardiovascular disease tend to be low. Several prospective
studies from Israel showed that an increased mortality rate
was associated with siesta among older people [44],
whereas a study from Greece suggested that siesta is pro-
tective against heart-related deaths, especially in working
men [45]. In addition, conflicting USA-based research has
found an increased risk of death associated with daytime
napping in both men and women [46]. Only naps of long
durations were found to be significant. In Japan, a study
suggested that daytime napping was associated with in-
creased risk of all-cause and cardiovascular death, but this
association was largely explained by concomitant comor-
bidity [47]. Clearly, the population evidence so far is in-
consistent and it may largely depend on differences in
cultural, environmental and demographic factors. It re-
mains therefore unclear whether daytime napping is ben-
eficial or a risk factor for or marker of ill health.
A recent programme of research on the effects of day-
time napping on health outcomes was completed in a rep-
resentative sample of British men and women. This
programme was carried out in the EPIC-Norfolk prospec-
tive cohort study, in which over 16,000 participants
provided information on their sleeping patterns, including
sleep duration, time in bed and daytime napping. They
were then followed-up for up to 13 years [48]. After
allowing for potential known confounders, daytime nap-
ping was significantly associated with an increased risk
of dying [49•]. For naps of less than 1 h, the risk was
increased by an average 14%, whereas for naps longer than
1 h, the risk increased further to an average 32% (Table 1).
The risk was also more pronounced for deaths from respi-
ratory diseases and in individuals older than 65 years [49•].
In the same study, daytime napping has been associated
with an increased risk of developing type-2 diabetes (2.5-
fold higher), especially when associated with short dura-
tion of sleep (< 6 h per night) [50•]. Finally, a similar
increased risk of chronic respiratory disease was detected
among shorter (< 1 h) and longer (≥ 1 h) naps, with a dose-
dependent effect of 52 and 72% increased risk,
respectively [51]. Comprehensive systematic reviews con-
firm these results [52•, 53•].
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Long Sleep Duration and Ill Health
It is important to mention that the associations between dura-
tion of sleep and health outcomes, whether morbid or fatal,
show clear-cut and consistent U-shaped curveswith the lowest
risk usually seen between 6 and 8 h per night and increased
risks also detectable for ‘long’ duration of sleep (> 8 h per
night) [21•, 27, 37••, 39, 40••, 41•]. However, the evidence
does not fulfil all the necessary criteria for implying causality
(in particular absence of plausible biological mechanisms), the






Environment (physical, social, work) Genetics
Fig. 2 Possible mechanistic pathways linking short duration of sleep and
adverse cardiovascular health. BP blood pressure, HbA1c haemoglobin
A1c, HDL high-density lipoprotein cholesterol, HR heart rate, LDL low-
density lipoprotein cholesterol, PAI-1 plasminogen activator inhibitor-1,
SNS sympathetic nervous system, SWS slow-wave sleep, Trigs
triglycerides. (Adapted with permission from Miller MA, Cappuccio
FP. J Hum Hypert 2013; 27: 583–588) [42]
Table 1 Summary table of the
prospective associations between
day-time napping and risk of
disease and death in the EPIC-
Norfolk population cohort of men
and womena
Outcome Groups Sample size Relative risk 95% C.I.
Type-2 diabetes [48] No napping 9613 Ref
Napping 3851 1.30 1.01–1.69
Respiratory disease [49•] No napping 7878 Ref
Nap < 1 h 2831 1.32 1.15–1.52
Nap ≥ 1 h 269 1.54 1.14–2.09
Chronic lower respiratory disease [49•] No napping 7878 Ref
Nap < 1 h 2831 1.52 1.18–1.96
Nap ≥ 1 h 269 1.72 1.01–2.92
All-cause mortality [47] No napping 11,493 Ref
Nap < 1 h 4412 1.14 1.02–1.27
Nap ≥ 1 h 469 1.32 1.04–1.68
a Results are expressed as relative risk (95% confidence intervals) between napping and reference category
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current interpretation is that long duration of sleep is rather a
marker or a symptom of pre-clinical ill health. However, fur-
ther research is needed.
Conclusions
There is a strong and consistent association between short
duration of sleep and cardio-metabolic risk factors and out-
comes. The associations may reflect causality [6] as the effects
are strong (large relative risks); they are consistent (confirmed
in different populations for several end-points), they show a
temporal sequence (short sleep preceding end-points), there is
a consistent threshold of effects, there are several potential
plausible biological mechanisms involved (genetic, molecu-
lar, cellular, physiological), and the reversibility of the effect is
confirmed when tested in controlled trial conditions (at least in
the short-term). Day-time napping and long duration of sleep
are also associated with ill health and worse health outcomes.
These associations are more likely to reflect the fact that nap-
ping and long sleep may be markers of compensation of sleep
deprivation (forced day-time napping) or of sub-clinical
chronic and/or debilitating ill health.
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